Multiple Sclerosis: Where do we go from here?
Multiple sclerosis (MS) is the most common cause of neurological disability in young populations after trauma and represents a significant personal, social, and economic public health burden. The clinical course and response of MS to therapy is highly heterogeneous, but most patients progress from a...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
European Medical Journal
2016-07-01
|
| Series: | European Medical Journal Neurology |
| Subjects: | |
| Online Access: | http://emjreviews.com/wp-content/uploads/Multiple-Sclerosis-Where-do-we-go-from-here...pdf |
| _version_ | 1811305288282669056 |
|---|---|
| author | Marta Tejera-Alhambra Lidia Fernández-Paredes Clara de Andrés Silvia Sánchez-Ramón |
| author_facet | Marta Tejera-Alhambra Lidia Fernández-Paredes Clara de Andrés Silvia Sánchez-Ramón |
| author_sort | Marta Tejera-Alhambra |
| collection | DOAJ |
| description | Multiple sclerosis (MS) is the most common cause of neurological disability in young populations after trauma and represents a significant personal, social, and economic public health burden. The clinical course and response of MS to therapy is highly heterogeneous, but most patients progress from a relapsing-remitting disease course, in which patients may respond to immunomodulatory drugs, to a steady progression and neurodegeneration that is unresponsive to any currently available treatment. In the last few years, novel disease-modifying therapies for MS have become available but the aetiology of the disease remains an enigma. The search for clinical biomarkers that are able to stratify MS patients and allow the personalisation of treatment strategies, has developed greatly in recent years though only a few have been integrated into routine clinical practice. |
| first_indexed | 2024-04-13T08:22:48Z |
| format | Article |
| id | doaj.art-bdc3b318b1264827b3451d4f683c592d |
| institution | Directory Open Access Journal |
| issn | 2054-4529 |
| language | English |
| last_indexed | 2024-04-13T08:22:48Z |
| publishDate | 2016-07-01 |
| publisher | European Medical Journal |
| record_format | Article |
| series | European Medical Journal Neurology |
| spelling | doaj.art-bdc3b318b1264827b3451d4f683c592d2022-12-22T02:54:35ZengEuropean Medical JournalEuropean Medical Journal Neurology2054-45292016-07-01418495Multiple Sclerosis: Where do we go from here?Marta Tejera-Alhambra0Lidia Fernández-Paredes1Clara de Andrés2Silvia Sánchez-Ramón3Medical Department, Inmunotek, S.L., Madrid, Spain Department of Clinical Immunology, Hospital Clínico San Carlos, Madrid, SpainDepartment of Neurology, Hospital General Universitario Gregorio Marañón, Madrid, Spain Department of Clinical Immunology, Hospital Clínico San Carlos, Madrid, SpainMultiple sclerosis (MS) is the most common cause of neurological disability in young populations after trauma and represents a significant personal, social, and economic public health burden. The clinical course and response of MS to therapy is highly heterogeneous, but most patients progress from a relapsing-remitting disease course, in which patients may respond to immunomodulatory drugs, to a steady progression and neurodegeneration that is unresponsive to any currently available treatment. In the last few years, novel disease-modifying therapies for MS have become available but the aetiology of the disease remains an enigma. The search for clinical biomarkers that are able to stratify MS patients and allow the personalisation of treatment strategies, has developed greatly in recent years though only a few have been integrated into routine clinical practice.http://emjreviews.com/wp-content/uploads/Multiple-Sclerosis-Where-do-we-go-from-here...pdfBiomarkersclinical activityMultiple sclerosis (MS) |
| spellingShingle | Marta Tejera-Alhambra Lidia Fernández-Paredes Clara de Andrés Silvia Sánchez-Ramón Multiple Sclerosis: Where do we go from here? European Medical Journal Neurology Biomarkers clinical activity Multiple sclerosis (MS) |
| title | Multiple Sclerosis: Where do we go from here? |
| title_full | Multiple Sclerosis: Where do we go from here? |
| title_fullStr | Multiple Sclerosis: Where do we go from here? |
| title_full_unstemmed | Multiple Sclerosis: Where do we go from here? |
| title_short | Multiple Sclerosis: Where do we go from here? |
| title_sort | multiple sclerosis where do we go from here |
| topic | Biomarkers clinical activity Multiple sclerosis (MS) |
| url | http://emjreviews.com/wp-content/uploads/Multiple-Sclerosis-Where-do-we-go-from-here...pdf |
| work_keys_str_mv | AT martatejeraalhambra multiplesclerosiswheredowegofromhere AT lidiafernandezparedes multiplesclerosiswheredowegofromhere AT claradeandres multiplesclerosiswheredowegofromhere AT silviasanchezramon multiplesclerosiswheredowegofromhere |